Permira seeks $4bn for sale of contract drugmaker Cambrex
Trump’s threat of pharmaceutical tariffs has boosted investor interest in US drugmakers
Related reading
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Europe races to placate pharma as Donald Trump turns up the pressure
Tariff deals with the US have bought time but investment momentum is elsewhere
Healthcare companies set for deals spree as drug patents expire
A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump’s policies
UK urges pharma companies to invest after reaching drug pricing deal with US
Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
US drugmakers threaten to withhold products from Europe over prices
Pharmaceutical companies seek to make up any lost revenue after striking deals with Donald Trump to lower costs in US